DE1956481A1 - Verfahren zur Bestimmung von Lipoproteiden - Google Patents
Verfahren zur Bestimmung von LipoproteidenInfo
- Publication number
- DE1956481A1 DE1956481A1 DE19691956481 DE1956481A DE1956481A1 DE 1956481 A1 DE1956481 A1 DE 1956481A1 DE 19691956481 DE19691956481 DE 19691956481 DE 1956481 A DE1956481 A DE 1956481A DE 1956481 A1 DE1956481 A1 DE 1956481A1
- Authority
- DE
- Germany
- Prior art keywords
- polymer
- lipoproteins
- chylomicrons
- test liquid
- lipoproteide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004895 Lipoproteins Human genes 0.000 title claims description 44
- 108090001030 Lipoproteins Proteins 0.000 title claims description 44
- 238000000034 method Methods 0.000 title claims description 33
- 229920000642 polymer Polymers 0.000 claims description 31
- 108010004103 Chylomicrons Proteins 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 230000002776 aggregation Effects 0.000 claims description 11
- 238000004220 aggregation Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- -1 halide sodium chloride Chemical class 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- HWYGBPPFPNZPGQ-IHWYPQMZSA-N (z)-2-methylbut-2-enediamide Chemical compound NC(=O)C(/C)=C\C(N)=O HWYGBPPFPNZPGQ-IHWYPQMZSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1525568A SE326057B (enrdf_load_stackoverflow) | 1968-11-11 | 1968-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1956481A1 true DE1956481A1 (de) | 1970-06-11 |
Family
ID=20300387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691956481 Pending DE1956481A1 (de) | 1968-11-11 | 1969-11-10 | Verfahren zur Bestimmung von Lipoproteiden |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE1956481A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2023010A1 (enrdf_load_stackoverflow) |
| SE (1) | SE326057B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077449A1 (de) * | 1981-08-27 | 1983-04-27 | Roche Diagnostics GmbH | Verfahren zur Bestimmung der beta-Lipoproteinfraktion (LDL) in Körperflüssigkeiten |
-
1968
- 1968-11-11 SE SE1525568A patent/SE326057B/xx unknown
-
1969
- 1969-11-07 FR FR6938554A patent/FR2023010A1/fr not_active Withdrawn
- 1969-11-10 DE DE19691956481 patent/DE1956481A1/de active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077449A1 (de) * | 1981-08-27 | 1983-04-27 | Roche Diagnostics GmbH | Verfahren zur Bestimmung der beta-Lipoproteinfraktion (LDL) in Körperflüssigkeiten |
Also Published As
| Publication number | Publication date |
|---|---|
| SE326057B (enrdf_load_stackoverflow) | 1970-07-13 |
| FR2023010A1 (en) | 1970-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2936307C2 (enrdf_load_stackoverflow) | ||
| DE1698180B2 (de) | Verfahren zur herstellung eines blutserum-bezugsnormals | |
| EP0092801B1 (de) | Verfahren zur Bestimmung der Low Density Lipoproteine (LDL) und Reagenz zu seiner Durchführung | |
| DE1523133C3 (de) | Vergleichsstandard zur kolorimetrischen Bestimmung des Gesamtcholesterins im menschlichen Blutplasma | |
| DE1944246A1 (de) | Verfahren und Vorrichtung zur quantitativen Bestimmung von chemischen Blutsubstanzen in Blutderivaten | |
| DE2406959C3 (de) | Anordnung und Verfahren zur Bestimmung von Antigenen | |
| DE2602997C2 (de) | Lyophilisierte Kollagenzubereitung und Verfahren zu ihrer Herstellung | |
| DE2806430A1 (de) | Verfahren zum nachweis und zur bestimmung des lipoproteins lp-x im serum | |
| DE2951783A1 (de) | Mittel zum eichen von geraeten zum messen der haematologischen werte von vollstaendigen blutproben und verfahren zu seiner herstellung | |
| DE1773363A1 (de) | Verfahren und Produkt zum Pruefen des Vorhandenseins von Haemoglobin S | |
| DE2840680A1 (de) | Verfahren zum messen von lipoproteidcholesterinen | |
| DE2262781A1 (de) | Verfahren zur bestimmung von anorganischem phosphat in organischen fluessigkeiten | |
| DE2533458A1 (de) | Verfahren und reagens zur bestimmung des gesamtcalciums in koerperfluessigkeiten | |
| DE60008159T2 (de) | Trenn- und Analyseverfahren für Lipoproteine, Vorrichtung zur Durchführung desselben, sowie ein die Vorrichtung enthaltendes System | |
| DE2037507A1 (enrdf_load_stackoverflow) | ||
| DE3010400A1 (de) | Verfahren zur klinischen trennung von (alpha) - und (beta) -lipoproteinen | |
| DE2722380A1 (de) | In-vitro-verfahren zur raschen trennung der mm- und mb-kreatin-kinaseisoenzyme in blutplasma oder -serum | |
| DE1956481A1 (de) | Verfahren zur Bestimmung von Lipoproteiden | |
| DE2309794B2 (de) | Testreagens zur Bestimmung von Ascorbinsäure | |
| EP0344580B1 (de) | Verfahren zum Bestimmen der relativen Mengen aller cholesterinhaltigen Lipoproteine in Körperflüssigkeiten | |
| DE69119576T2 (de) | Verfahren zur Abtrennung, Identifizierung und Quantifizierung von Isoenzymen und Isoformen der alkalischen Phosphatase | |
| DE69332764T2 (de) | Hydroxylamin enthaltendes kontrollreagenz | |
| WO2001048476A2 (de) | Gewinnung von biologischen komponenten aus körperflüssigkeiten | |
| DE3133937A1 (de) | Verfahren zur bestimmung von ldl | |
| DE69213409T2 (de) | Bioysnthetische gehirnruckenmarkflussigkeitskontrolle und verfahren zu deren herstellung |